INTERIM REPORT JANUARY – MARCH 2005

• Turnover during the period amounted to SEK 198.0 (179.7) million, which is an increase of 10 percent. • Operating income amounted to SEK -0.2 (-1.0) million. • Net income after tax amounted to SEK 3.5 (3.3) million. • Earnings per share were SEK 0.14 (0.13). • The patent dispute in the USA has been discontinued. • Continued good growth within the Hospital Healthcare product area, 50 percent. Queries should be addressed to: Erika Kjellberg Eriksson, Vice President and CFO, Tel: + 46 (0)70-974 90 20 Anne Rhenman, Director Investor Relations and Corporate Communications, Tel: + 46 (0)70-974 90 15